Corporate Reports and Filings
2018 Financial Statements
2017 Financial Statements
- 2017 Annual Report
- 2017 Semi-Annual Report (unaudited)
- 2017 Full Year – earnings release
- 2017 First Half – earnings release
2016 Financial Statements
2015 Financial Statements
2012 Financial Statements
The statements contained in this website which are not historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company’s control, with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
HemaCare voluntarily delisted from NASDAQ in 2012 due to the significant costs of remaining a public company, and is no longer required to be registered with the SEC. HemaCare is currently traded on the OTCMKTS (Pink Sheets) under “HEMA”.
For more information, please contact the Investor Relations department at (877) 310-0717 (option 8).
Note: It is the policy of HemaCare not to respond to email inquiries via return email. If you have a specific question regarding HemaCare, please call.